Rx Product News (May 2018)

Pharmacy Times, May 2018 Skin & Eye Health, Volume 84, Issue 5

Read about the Rx products featured in May.

Becton Dickinson and Company

INDICATION: Becton Dickinson and Company has launched BD Veo, the new brand name for the company’s line of insulin syringes with BD Ultra-Fine 6mm needles. BD Veo Insulin Syringes feature the shortest BD Ultra-Fine 6mm needle, ensuring that people with diabetes who use insulin syringes to inject insulin have less to fear.

DOSAGE FORM: Injection

FOR MORE INFORMATION: bd.com

TAVALISSEMANUFACTURED BY: Rigel Pharmaceuticals Inc

INDICATION: The FDA has approved fostamatinib disodium hexahydrate (Tavalisse) to treat adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Tavalisse is an oral spleen tyrosine kinase inhibitor that targets the underlying autoimmune cause of the disease by impeding platelet destruction, providing an important treatment option for adult patients with chronic ITP.

DOSAGE FORM: Tablets, 100 mg orally, twice daily

FOR MORE INFORMATION: rigel.com

CRYSVITAMANUFACTURED BY: Ultragenyx Pharmaceutical Inc

INDICATION: The FDA has approved burosumab (Crysvita), the first drug approved to treat adults and children 1 year and older who have x-linked hypophosphatemia (XLH). This rare, inherited form of rickets causes low levels of phosphorus in the blood and leads to impaired bone growth and development in children and adolescents, as well as problems with bone mineralization throughout a patient’s life.

DOSAGE FORM: Subcutaneous injection, 0.8 mg/kg of body weight rounded to the nearest 10 mg, every 2 weeks (pediatric) or 1 mg/kg body weight rounded to the nearest 10 mg, up to a maximum dose of 90 mg, every 2 weeks (adults)

FOR MORE INFORMATION: ultragenyx.com

PRAXBINDMANUFACTURED BY: Boehringer Ingelheim Pharmaceuticals Inc

INDICATION: The FDA has approved idarucizumab (Praxbind), the specific reversal agent for dabigatran etexilate mesylate (Pradaxa). Praxbind is indicated for patients treated with Pradaxa when reversal of dabigatran’s anticoagulant effects is needed for emergency surgery or urgent procedures for life-threatening or uncontrolled bleeding.

DOSAGE FORM: Intravenous, 5 g, provided in 2 vials, each containing 2.5g/50 mL idarucizumab

FOR MORE INFORMATION: boehringer-ingelheim.us